HC Wainwright Analysts Lower Earnings Estimates for ASMB

Assembly Biosciences, Inc. (NASDAQ:ASMB) – HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for Assembly Biosciences in a report released on Thursday, March 26th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will earn ($0.73) per share for the quarter, down from their previous forecast of ($0.50). HC Wainwright currently has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences’ Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at $3.51 EPS, FY2026 earnings at $1.61 EPS, FY2027 earnings at ($0.64) EPS, FY2028 earnings at $0.32 EPS and FY2029 earnings at ($2.83) EPS.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings data on Thursday, March 19th. The biopharmaceutical company reported $2.48 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $2.99. The company had revenue of $42.47 million during the quarter, compared to the consensus estimate of $7.42 million. Assembly Biosciences had a negative net margin of 8.47% and a negative return on equity of 5.63%.

A number of other analysts have also commented on ASMB. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $41.75.

Assembly Biosciences Price Performance

NASDAQ:ASMB opened at $27.70 on Monday. The company has a market cap of $439.32 million, a P/E ratio of -37.43 and a beta of 1.11. Assembly Biosciences has a twelve month low of $7.75 and a twelve month high of $39.71. The business has a 50 day moving average price of $27.93 and a two-hundred day moving average price of $29.84.

Institutional Investors Weigh In On Assembly Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE grew its stake in shares of Assembly Biosciences by 6,382.7% in the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 3,319 shares in the last quarter. Seven Fleet Capital Management LP bought a new stake in Assembly Biosciences during the fourth quarter worth $147,000. Acadian Asset Management LLC lifted its stake in Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 6,823 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in Assembly Biosciences in the fourth quarter valued at $228,000. Finally, Virtus Investment Advisers LLC bought a new position in shares of Assembly Biosciences in the 4th quarter valued at about $251,000. Institutional investors own 19.92% of the company’s stock.

Trending Headlines about Assembly Biosciences

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: Wall Street Zen upgraded ASMB to a “Strong‑Buy,” which supports bullish investor sentiment and could attract buying interest. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy rating with a $50 target and raised several multi‑year forecasts (notably FY2026 and FY2028), signaling conviction in ASMB’s longer‑term outlook despite near‑term variability. Article Title
• Neutral Sentiment: Recent compilation of research analyst Q1 earnings predictions provides a range of expectations investors can use to position ahead of the quarterly report; this keeps Q1 results a near‑term catalyst. Article Title
• Negative Sentiment: HC Wainwright trimmed near‑term EPS estimates (Q1–Q3 2026) and cut FY2027 and FY2029 forecasts, which may be pressuring the stock as it raises questions about short‑term profitability and execution risk. MarketBeat ASMB coverage

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.